Clinical Trial Update: Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib in combination with docetaxel for advanced non-squamous non-small cell lung cancer. Status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN